Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q8065569> ?p ?o }
Showing triples 1 to 59 of
59
with 100 triples per page.
- Q8065569 subject Q6809004.
- Q8065569 abstract "Zalutumumab (proposed trade name HuMax-EGFr) is a fully human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFr). It is a product developed by Genmab in Utrecht, the Netherlands. Specifically, zalutumumab is designed for the treatment of squamous cell carcinoma of the head and neck (SCCHN), a type of cancer. The current treatment for SCCHN includes tyrosine kinase inhibitors and human monoclonal antibodies.".
- Q8065569 atcPrefix "none".
- Q8065569 casNumber "667901-13-5".
- Q8065569 wikiPageWikiLink Q10641483.
- Q8065569 wikiPageWikiLink Q12078.
- Q8065569 wikiPageWikiLink Q14599311.
- Q8065569 wikiPageWikiLink Q14864695.
- Q8065569 wikiPageWikiLink Q14865565.
- Q8065569 wikiPageWikiLink Q14903573.
- Q8065569 wikiPageWikiLink Q14905188.
- Q8065569 wikiPageWikiLink Q14908037.
- Q8065569 wikiPageWikiLink Q1616930.
- Q8065569 wikiPageWikiLink Q1671731.
- Q8065569 wikiPageWikiLink Q1783924.
- Q8065569 wikiPageWikiLink Q181876.
- Q8065569 wikiPageWikiLink Q187640.
- Q8065569 wikiPageWikiLink Q188941.
- Q8065569 wikiPageWikiLink Q189092.
- Q8065569 wikiPageWikiLink Q204711.
- Q8065569 wikiPageWikiLink Q2076526.
- Q8065569 wikiPageWikiLink Q2112244.
- Q8065569 wikiPageWikiLink Q242736.
- Q8065569 wikiPageWikiLink Q332181.
- Q8065569 wikiPageWikiLink Q332823.
- Q8065569 wikiPageWikiLink Q392227.
- Q8065569 wikiPageWikiLink Q409325.
- Q8065569 wikiPageWikiLink Q420511.
- Q8065569 wikiPageWikiLink Q422248.
- Q8065569 wikiPageWikiLink Q422582.
- Q8065569 wikiPageWikiLink Q424396.
- Q8065569 wikiPageWikiLink Q425265.
- Q8065569 wikiPageWikiLink Q483261.
- Q8065569 wikiPageWikiLink Q4914012.
- Q8065569 wikiPageWikiLink Q510025.
- Q8065569 wikiPageWikiLink Q5156356.
- Q8065569 wikiPageWikiLink Q539568.
- Q8065569 wikiPageWikiLink Q5425270.
- Q8065569 wikiPageWikiLink Q576711.
- Q8065569 wikiPageWikiLink Q6589727.
- Q8065569 wikiPageWikiLink Q6593810.
- Q8065569 wikiPageWikiLink Q6809004.
- Q8065569 wikiPageWikiLink Q681817.
- Q8065569 wikiPageWikiLink Q7117843.
- Q8065569 wikiPageWikiLink Q715347.
- Q8065569 wikiPageWikiLink Q803.
- Q8065569 wikiPageWikiLink Q898401.
- Q8065569 wikiPageWikiLink Q906415.
- Q8065569 wikiPageWikiLink Q909628.
- Q8065569 wikiPageWikiLink Q974135.
- Q8065569 atcPrefix "none".
- Q8065569 casNumber "667901".
- Q8065569 type ChemicalSubstance.
- Q8065569 type Drug.
- Q8065569 type ChemicalObject.
- Q8065569 type Thing.
- Q8065569 type Q8386.
- Q8065569 comment "Zalutumumab (proposed trade name HuMax-EGFr) is a fully human IgG1 monoclonal antibody (mAb) directed towards the epidermal growth factor receptor (EGFr). It is a product developed by Genmab in Utrecht, the Netherlands. Specifically, zalutumumab is designed for the treatment of squamous cell carcinoma of the head and neck (SCCHN), a type of cancer. The current treatment for SCCHN includes tyrosine kinase inhibitors and human monoclonal antibodies.".
- Q8065569 label "Zalutumumab".